Clinical Trials · NCT00135330
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 137
- Start date
- Oct 2005
- Locations
- 19 sites, United States
- Primary endpoint
- Change in ASIiAUC During a Hyperglycemic Clamp Test.